Hepatitis C New Zealand

March 8, 2010

Hepatitis C New Zealand Blog March 2010

Hepatitis C conference  Whakatane 2010

Past Failures and New Solutions in Hepatitis B and C control in New Zealand and the Asia Pacific region
Tariana Turia - NZ Viral Hepatitis Conference 2010

Tuatahi me mihi atu ki te mana whenua. Tena koutou o Mataatua waka. Tena hoki koutou o nga mata waka kua whakarauika nei i raro i te karanga o te ra

Tena koutou i runga i te rangimarie. Tena koutou i runga i nga maharatanga mo ratou kua wheturangitia.

No reira, tena tatou katoa

I want to thank the Hepatitis Foundation of New Zealand for the honour of being invited to open this third New Zealand Viral Hepatitis Conference.

I acknowledge the local people of this rohe, and I thank them for their generosity in hosting us here in Whakatane.

I extend a particular welcome to our international guests:

* Professor Mitchell Shiffman from the United States;
* Professor Andrew Lloyd from Australia;
* Dr Morris Sherman from Canada and
* Dr James Fung from Hong Kong.

While both Hepatitis B and C viruses are notifiable conditions under the Health Act, it is only cases of acute infection which require to be notified to the Medical Officer of Health.

Alongside with the lack of awareness that comes from being asymptomatic; people with hepatitis may experience stigma and discrimination which compounds the problems of living with the virus.

So the call to do better is an important one.

We must continue to raise awareness, leading to increased testing and diagnosis.
Well spoken words from Tariana Turia

Life after liver transplant

Hi, This is my first post of my Video Diary following my Liver Transplant and my continued fight against my Hepatitis C infection/virus. Just a quick one to saay hello - I’ve never done video before and so let’s hope for all our sakes that I get better at it soon!

Please check out my blog: http://www.ianquill.blogspot.com - Thanks for watching…. Ian Quill

Hepatitis C Drug Trails NZ March 2010

Four drug trials for Hepatitis C in New Zealand at the moment (March 2010)
http://clinicaltrials.gov/ct2/results?term=hepatitis+c+New+zealand&recr=Open
1, TMC435-TiDP16-C206: A Safety and Efficacy Study in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

2,  A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

3, Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive

4, Antiviral Activity of AZD7295 in HCV Carriers

Doctor  Magdalena Harris

thesis is available online now

Negotiating the pull of the normal: embodied narratives of living with hepatitis C in New Zealand and Australia (2010)
Harris, Magdalena , National Centre In HIV Social Research, Faculty Of Arts & Social Sciences, UNSW
My status as a person living with hepatitis C informed all aspects of this research project; I therefore also include my own experiences, foregrounding researcher reflexivity and the co-constructed nature of the interview process.

“ My aims are both practical and theoretical. On a practical level I explore the experiences of people living with hepatitis C in order to inform recommendations for policy, research and practice, while also working to elucidate and employ an approach that allows for an analysis of the ill body as a lived experiencing agent, located in a substantive web of connections whereby discourse, corporeality and sociality, inform and mediate one another. To this end I employ a “political phenomenology” influenced by phenomenological and poststructuralist theoretical approaches. The central, previously under-researched, issues that arose in participants’ narratives structure the chapter outline, with results chapters focusing on participants’ experiences of diagnosis, living with hepatitis C, stigma, support group membership, alcohol use, and hepatitis C treatment.

For many participants, it was found that living with hepatitis C was a liminal experience where distinctions between what it was to be healthy or ill were not clear-cut. Indeed, many of the participants’ narratives exposed the inadequacy of Western binary categorisations to speak to their experiences of living with hepatitis C. Throughout this thesis it can be seen that the meanings that participants ascribed to health, illness, and their hepatitis C were fluid and contextual, informed by the interplay of corporeality and discourse. From this interplay comes the ability to speak into the gaps of dominant discourses, creating the potential for the disruption, or subtle realignment, of normative ways of knowing. “
Download  your copy here
http://unsworks.unsw.edu.au/vital/access/manager/Repository/unsworks:7899

Congratulations  Dr Harris from all your peers.

The best of health
www.hcv.org.nz

January 30, 2010

Hepatitis C New Zealand blog January 2010 New Zealand Viral Hepatitis Whakatane 2010

Hepatitis C New Zealand blog January 2010 New Zealand Viral Hepatitis Whakatane 2010

New Zealand Viral Hepatitis 3rd NZ Conference Whakatane 2010

Friday 05 March – Saturday 06 March 2010
War Memorial Complex, Whakatane, New Zealand

Invited Speakers: Professor Mitchell Shiffman, USA

Professor Andrew Lloyd, Australia

Dr Morris Sherman, Canada

Dr James Fung, Hong Kong

Around half the conference will  be about hepatitis B and the other half hepatitis C

With topics such as

Relevance of viral  load; is it a predictor to HCC?  James Fung

Multidisciplinary approach of HCC in NZ  John McCall or Adam Bartlet

Therapies available for patients with HCC in NZ Catherine Stedman

State of the Art Lecture

Optimisation of Outcomes with current standard-of-care” (on use of baseline and
on-treatment responses (RVR, EVR) to individualiase therapy, weight-based RBV).
What’s next – direct acting antivirals (DAAs )Mitch Shiffman

HCV in Correctional Facilities

HCV prevention, treatment and follow-up in prison populations Andrew Lloyd

HCV in NZ correctional facilities Frank Weilert

NZ model in an Auckland prison Steve Gerred

Difficult-to-treat patients

State of Art Lecture
“Approaches to non-responders – retreatment, induction dosing IFN,
higher dosing RBV, maintenance therapy – do they work”  Mitch Shiffman

Alternative therapies for HCV

Is there alternative therapies for HCV treatment and do they work? TBA;   College of natural therapies

Middlemore audit of patients taking alternative therapy Jacinda Ryan

Hepatotoxic therapies Sarah Fitt

Debate: Should there be a national register for chronic HBV & HCV?

You can find out more about the conference at the hepatitis foundation of New Zealand Website here

http://www.hepfoundation.org.nz/conferencep.html

and register here

http://www.hepfoundation.org.nz/RegistrationForm2010.pdf

Our invite must have got lost in the mail and our budget of zero precludes travel. The joys of the peer based NGO.

New Zealand hep c news letter

Got my first email copy of the New Zealand hep c news letter , a joint effort by the Auckland Christchurch and Dunedin Hepatitis C Resources centres.

Well actually I accidentally deleted it so if you want to check it out Hepatitis C resource centre  0800 224372 (0800 22 HEPC)

A viral hepatitis testing pilot project in 19 pharmacies across the country has found a hepatitis B or C positive patient in every 6 tests conducted.

I mentioned this chemist based anonymous testing for hepatitis at English pharmacies a while back; the results of the trial have been interesting

19 pharmacies in 5 PCT areas offered free, on-demand hepatitis B and C dried blood spot tests to clients who had been at risk of contracting viral hepatitis as part of a 3-month pilot project organised by The Hepatitis C Trust. Across the pharmacies a total of 234 tests were conducted, diagnosing 35 people with hepatitis C (15% of tests) and 4 people with hepatitis B (2% of tests). This is a far higher proportion of hepatitis C positive diagnoses than found in GP surgeries, where 4% of tests find positive hepatitis C patients and 2% of tests find hepatitis B patients.

Dev Dalvar from D R Pharmacy in Sandwell PCT commented on the pilot: “Offering hepatitis B and C tests in my pharmacy has been a huge benefit to the local community. The people diagnosed will now be able to access potentially life-saving treatment and many customers are more aware about the viruses and risk factors.

Charles Gore, Chief Executive of The Hepatitis C Trust said: “It is a tragedy that increasing numbers of people with hepatitis C are dying, often because they have been living with the hepatitis B or C undiagnosed for years, even decades. There are at least 100,000 people living with the hepatitis C unawares but only 8,000 people were diagnosed last year. We desperately need a new approach to testing that will find the undiagnosed patients and this pilot study shows pharmacy testing could be just what is needed.

A series of Hepatitis C videos from the Harm reduction works

HIV, hepatitis C and injecting drug use, part 2: The sharing of injecting equipment

Best of health for 2010

www.hcv.org.nz

December 14, 2009

Hepatitis C New Zealand laboratory notification

Strategic Directions for Hepatitis C improving access to and uptake of hepatitis C treatment services.

One of the key points of this unreleased document, (Rumour has it will be never released as it involves the New Zealand Ministry of Health  acknowledging they have a major problem and actually doing something about it , i.e. spending money.)

Key action area 4 Improving knowledge about HCV prevalence in the New Zealand population and within sub groups.

HCV is a notifiable disease in New Zealand, but is really notified.

In Australia they operate a national registry for HCV the register gathers notifications from care providers and reference laboratories. Reference laboratory notifications in Australia make up 90% of all notifications.

It seems logical then to introduce  a laboratory notification system here in New Zealand to give accurate information on the number of people of people in New Zealand with HCV similar to what already occurs for HIV and aids notifications.

It seem a fundamental first step to dealing with any contagious disease is to effectively measure it’s prevalence we hope 2010 is the year the New Zealand  Ministry of health make this a priority.

Small chance of being diagnosed and treated for hepatitis C in New Zealand

I had an interesting conversation the other day.  Bob was saying how great he felt after completing Hepatitis C Treatment a couple of years back. We agreed the treatment sucked but the change in your health after completing successful treatment can be miraculous, he claimed to feel like he was 16 again, although I don’t feel that good the energy levels were back and I do feel healthy.

Bob claimed he could get up in the early morning climb a mountain shoot a deer, gut it out and climb back down with a dead deer on his back and then go and work all day. Me I’m just happy not to be constantly exhausted all the time.

Small chance of being diagnosed and treated for hepatitis C in New Zealand. Based on the fact that nationally approximately 300 people are treated per year and 50,000 are estimated to have hepatitis C. Made me feel lucky and thankful.

It always amazes just how wide spread people with Hepatitis C are and how little they talk about it because of the perceived stigma of the disease.

Some don’t seek hepatitis C treatment

NEW YORK, Nov. 10 (UPI) — U.S. researchers say patients with more difficult to treat forms of hepatitis C are half as likely to get treatment as those with easier to treat forms.

Dr. Thomas McGinn of Mount Sinai School of Medicine said the researchers also found marital status also affected whether patients chose treatment for hepatitis C.

“Overall, in general only about 30 percent of hepatitis C patients choose to initiate treatment for the disease,” the senior author said in a statement. “It’s a huge problem that needs to be addressed. This study confirms that genotype is a major barrier to treatment. We hope these findings will lead to changes in how physicians approach patient care in a way that increases the rate of treatment initiation.”

In this study, of the 168 treatment-eligible patients, 41 began treatment and 127 did not — or 24 percent sought treatment. Patients with genotypes 1 and 4 of the disease, which are less responsive to treatment, were less likely to initiate treatment, as were unmarried patients and patients with multiple diseases, or medical comorbidities.

The findings are published in the of Journal of Health Care for the Poor and Underserved.

http://www.upi.com/Health_News/2009/11/ … 257886770/

Hep c new treatment tested New Zealand

A recent news release about some successful hepatitis C   New Zealand Drug trial’s,  Interesting about US not allowing drug  trial within US, but ok for New Zealand and Australia etc

Hep c new treatment tested Wellington, Nov 6 NZPA - Researchers are claiming success in a New Zealand clinical trial of antiviral drugs used against the hepatitis C virus (HCV).

A combination of two experimental anti virals led to dramatic reductions in viral loads during the 13-day pilot trial, according to Edward Gane, of Auckland Clinical Studies.

Hepatitis C is a virus carried in the blood that can damage the liver, leading to cirrhosis (scarring), failure and cancer, and it has infected more than 30,000 New Zealanders.

The Food and Drug Administration (FDA) in the United States does not permit the illness to be treated without interferon- because of concerns such treatments could provoke resistance to drugs that might otherwise remain effective.

The drugs’ lead developer, Roche, said in a statement that phase two clinical trials would start early next year, though the studies must continue to be conducted outside the US because of the FDA policy on interferon.

Health Cheque

Been reading Health Cheque the truth we should all know about New Zealand’s public health system. A new book Gareth Morgan and Geoff Simmons

A great read about the New Zealand Health system, dissecting the subject well, what gets funded who gets treated; it’s well written and balanced in its approach.  Haven’t finished book yet but it is surprisingly readable, and insightful so far

Health Cheque link

NZ Needle exchange success

Thursday, 19 November, 2009 - 14:40 scoop link

Recent data has confirmed that New Zealand’s Needle Exchange Programme is one of the most successful in the world, but we could do even better, says Needle Exchange New Zealand National “Manager Charles Henderson.

He said, however, that a reduction in hepatitis C levels was the most pleasing result of all.

“Our 2004 study revealed that nearly three out of four New Zealand injecting drug users had been exposed to the hepatitis C virus. This year’s study indicates a significant drop in this statistic to around half.

Hepatitis C is a virus that can cause liver disease, leading to years of ill health and possibly even death. It can only be caught via the exchange of blood from an infected person. It is a significant risk for those drug users who share needles or other injecting paraphernalia.

The latest Household Drug Survey indicates 2 percent of New Zealanders inject or have injected drugs at some point in their lives, many of whom do so only occasionally or recreationally. This means 85,000 people are potentially susceptible to blood-borne viruses from drug use.” Charles Henderson

I   think needle exchanges are a good place to engage with active drug users with hepatitis C.  I think they are a key public health initiative New Zealand can be proud off. Lots of potential for preventative health savings in getting the needle exchange program working better and decreasing future spread of hepatitis C.

It is important to realise that the majority of people with hepatitis c don’t attend needle exchanges any more , Charles figures seem to suggest a 25% decrease in the numbers of people with hepatitis C attending  the needle exchange.

“The largest undiagnosed pool of people with HCV are likely to be those aged 40 – 60 years old, who were infected 25 – 40 years ago, who at that time occasionally (or even once) injected illicit drugs , but went on to lead ‘conventional lives’.  (Strategic Directions for Hepatitis C : Improving access to and uptake of hepatitis C treatment services.)

It seems that targeting hepatitis C education funding and programs to needle exchange programs misses the largest group of people with hepatitis C.   The needle exchange is a fantastic cost effective prevention and education program targeting active drug users not all people with Hepatitis c are active drug users.  Associating drug use and hepatitis C just builds and reinforces the stigma associated with Hepatitis C.

Jim Anderton MP made a great speech when opening the Christchurch needle exchange new location.

Anderton: Opening the new Rodger Wright Centre
Friday, 20 November 2009, 2:56 pm
Press Release: Progressive Party

“As a politician, I know that to make a difference to peoples’ lives, more often than not, means going the extra mile. I thank you for your commitment.

I wish we didn’t need this programme. I wish we didn’t have drug use causing the harm it does, wrecking the lives of many people, and wrecking many communities. But it does happen. It will keep happening.

And if we care about vulnerable victims then our responsibility is to reduce the harm to them as much as we can. The needle exchange programme does just that and I continue to support it for that reason.”

scoop here

Injecting, Infection, Illness: Abjection and Hepatitis C Stigma

Magdalena Harris

While Social Research has documented the prevalence and ill effects of Hepatitis C related stigma,

Magdalena discuses ways in which this stigmas is constituted

Three components central to hepatitis C stigma

1. illicit injecting

2. infectiousness and

3. societal aversion to chronic illness

Magdalena is a peer a great writer and world expert on Hepatitis C.  I always enjoy reading and learning from what she has to say, this contains some déjà vu moments where she has managed to capture the essence of many people’s experiences with Hepatitis C. Well worth a read.

Injecting, Infection, Illness: Abjection and Hepatitis C Stigma

Get tested campaign

Get tested campaign from UK  Words of wisdom from Topper Headon and others about getting treated  Get tested get treated now.

Get Tested! from Ross Aitken on Vimeo.

Have a great Holiday season

Best of health

www.hcv.org.nz

November 3, 2009

New Zealand Hepatitis C Blog The good news

New Zealand Hepatitis C Blog The good news

The Good News about Coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease
progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).
The study found that patients with hepatitis C-related bridging fibrosis or cirrhosis who did not respond to standard disease treatment benefited
from increased coffee intake. An effect on liver disease was not observed in patients who drank black or green tea. Findings of the study appear
in the November issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Three cups a day and a 53% lower risk of progression that has to make coffee a good option for those with hep c.

http://www3.interscience.wiley.com/journal/122511224/abstract?CRETRY=1&SRETRY=0

The Good news for new treatment options  Telaprevir

Good news for People with Genotype one Hepatitis C is the latest results of the new drug telaprevir
Cork, Ireland (October 31, 2009) –Tibotec announced today results of a new study (VX950-C208), which showed that sustained virologic response (SVR)
was achieved in more than 80 percent of treatment-naïve patients with chronic genotype 1 hepatitis C virus (HCV) who took telaprevir, administered either
every 8 hours or every 12 hours, in combination with standard of care. Telaprevir, an investigational STAT-C (Specifically Targeted Antiviral Therapy for hepatitis C),
is being co-developed by Tibotec in collaboration with Vertex Pharmaceuticals. The study was presented today at the 60th Annual Meeting of the
American Association for the Study of Liver Diseases (The Liver Meeting).

In the phase II study, which enrolled 161 treatment-naïve genotype 1 patients, rates of SVR (defined as undetectable HCV RNA at 24 weeks after completion of treatment)
ranged from 81 to 85 percent in patients treated with the every 8 hour telaprevir-based regimen, and 82 to 83 percent in patients treated with the every twelve hour regimen.
Adverse events (AEs) were similar to those observed in other trials with telaprevir and were mainly haematologic (anaemia) and cutaneous (rash and pruritus) in nature.

For the vast majority of patients, these high SVR rates were obtained with only 24 weeks of total treatment (half the duration of current standard of care).
Total duration of treatment was decided using a criteria based on treatment response. Subjects who achieved undetectable HCV RNA at week 4
(rapid virologic response or RVR) and maintained this through week 20, were allowed to stop all treatment at week 24. Only 18% of subjects were required to continue standard treatment up to week 48.

Source: Johnson & Johnson Services

Good news for me

My post treatment 24 week viral load came back undetectable

testviralload

The Good news from www.womanaloud.co.uk

Had some good feedback from my last Blog post In particular from Tracy  at  http://www.womanaloud.co.uk/index.html A peer among peers.

” I wish you good health and a sharp pen. Raising awareness of hepatitis C is an uphill struggle… but day by day, one step at a time, it is happening. It is interesting to consider that, if we could get over the brain fog ; D, there are enough of us in the world with this condition, to form our own group/religion/club… if 180 million sufferers were all to shout on the same day, at the same time… mmm … I think I’ll put the kettle on. ”

Thanks Tracy great message. Just off to have a cup of tea myself,  maybe  a coffee as it seems that may be better for me.

Best of Health


www.hcv.org.nz

October 8, 2009

Hepatitis C New Zealand A dark and stormy night

Hepatitis C New Zealand  A dark and stormy night

Public Health Champion 2009 awarded by Public Health Association to Canterbury’s Cheryl Brunton

Dr Brunton’s work with hepatitis C began when she investigated an outbreak at Christchurch Prison in 1991. This led to an on-going interest in hepatitis C research and advocacy. She helped establish the Auckland and Christchurch Hep C support groups, was instrumental in founding the Christchurch Hepatitis C Resource Centre and was the inaugural chair of its trust board. She also took part in the development of the first national Hepatitis C Action plan.

“She continues to arrange conferences, workshops and training on Hep C, played a part in the establishment of the Hepatitis C community clinic in Christchurch, and is part of its advisory group.

I applaud any one working to improve things for people with Hepatitis C long my people care and make a difference, thanks Cheryl from everyone affected by Hepatitis  in New Zealand.

http://www.scoop.co.nz/stories/GE0909/S00025.htm

Prime minister with Hepatitis C

The Prime Minister of Mongolia S.Bayar is the first prime minister to publically announce their hepatitis C Status recently, Bayar was reported to have the viral infectious disease of Hepatitis C before he took office of prime minister. He said that the Prime Minister took a holiday of five working days only since he assumed office in November 2007. In Seoul, Lambaa said, Prime Minister Bayar is now receiving “interferon-based therapy”.

New issue Australian  Hep C  Review magazine available online a good read

The new issue of Australian Hep C magazine is available on line it has some interesting articles about hepatitis C but the one that caught my eye was a   article on drug trials for hepatitis c

Available here.

http://hepmagazines.realviewtechnologies.com/

C-een & Heard speakers program

Inviting a speaker to your agency or organisation provides an opportunity to:
•    Hear first hand personal experiences of people living with hepatitis C
•    Challenge the myths and stereotypes about hepatitis C
•    Address discriminatory attitudes in the workplace and elsewhere
•    Provide a holistic view of health (medical, social, personal)
•    Gain insight into the psychosocial issues associated with hepatitis C
•    Enhance existing training & education initiatives with personal perspectives

Maceon is a guy who lives in Sydney and is involved in community-based education and awareness raising in NSW, Australia. He features in a new DVD produced by the Hepatitis C Council of NSW. It contains stories from several different speakers and is used as a facilitation tool used when our Education and Development team conducts sessions outside the Sydney metropolitan region.

Interesting news story from America about the Hepatitis C hazards of the health care system,

Hep C nurse 20 years jail
Added: 28 September 2009
A former hospital surgical technician who may have infected dozens of surgical patients with hepatitis C by stealing their pain medication and swapping back needles tainted by the virus she carried pleaded guilty on Friday to US federal drug charges. Kristen Parker, 26, could have faced up to life in prison on the most serious charges, but accepted a 20-year prison sentence in a plea agreement with federal prosecutors. Ms. Parker admitted guilt to multiple charges of tampering with a consumer product and obtaining a controlled substance by deceit. Twenty-seven patients at two US hospitals where Ms. Parker worked last year and this year, in Denver and Colorado Springs, have tested positive for a strain of hepatitis C and have been linked to her care, according to state health records. Ms. Parker’s lawyer said outside the courthouse that he thought the lesser sentence was warranted in part by his client’s cooperation with health officials and the police since her arrest this summer

I have been impressed with the English web resource  www.harmreductionworks.org.uk

This website supports the harm reduction works campaign materials. The campaign was developed by Exchange Supplies for the National Treatment Agency as part of the implementation of the Department of Health publication Reducing Drug Related Harm: An Action Plan. The plan commits to reducing the burden of illness and death caused by illicit drug use through improved surveillance of service provision, improved delivery of harm reduction services, and information campaigns aimed at drug users and drug service providers.

http://www.harmreductionworks.org.uk/index.html

Harm reduction works  it has some great information on Hepatitis C  I like this video in particular how small is the hepatitis C Virus is.

Best of Health

www.hcv.org.nz

August 23, 2009

Current Clinical Drug Trials for Hepatitis C In New Zealand

New Zealand has up to six different drug trials currently in progress for Hepatitis C.
1    Recruiting     TMC435-TiDP16-C205: A Phase II Study of TMC435 in Combination With Pegylated Interferon Alpha-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
Condition:     Hepatitis C
Interventions:     Drug: PegIFNalpha-2a;   Drug: PegIFNalpha-2a;   Drug: Ribavirin PegIFNalpha-2a;   Drug: Ribavirin PegIFNalpha-2a;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Ribavirin;   Drug: TMC435 TMC435 Placebo;   Drug: TMC435 Ribavirin;   Drug: PegIFNalpha-2a;   Drug: TMC435 Placebo Ribavirin

2    Recruiting     A Study of Combination Treatment With an HCV Polymerase Inhibitor (Polymerase Inhibitor) and an HCV Protease Inhibitor (RO5190591) in Genotype 1 Chronic Hepatitis C Patients
Condition:     Hepatitis C, Chronic
Interventions:     Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591;   Drug: RO5024048/RO5190591

3    Recruiting     Safety and Efficacy of MK7009 Administered With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV)
Condition:     Chronic Hepatitis C Virus Infection
Interventions:     Drug: Comparator: Peg-INF;   Drug: Comparator: RBV;   Drug: Comparator: MK7009;;   Drug: Comparator: Placebo.;   Drug: Comparator: MK7009.;   Drug: Comparator: MK7009;   Drug: Comparator: Placebo;;   Drug: Comparator: Peg-INF.;   Drug: Comparator: RBV.

4    Recruiting   Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive
Condition:     Hepatitis C
Intervention:     Drug: clemizole hydrochloride

5    Recruiting     Antiviral Activity of AZD7295 in HCV Carriers
Condition:     Hepatitis C
Interventions:     Drug: AZD7295;   Drug: Placebo

6    Recruiting     Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
Condition:     Hepatitis C
Interventions:     Drug: VCH-222;   Drug: VCH-222;   Drug: VCH-222;   Drug: telaprevir

Interesting to discover so many trials underway in New Zealand and these are just the current ones.  I guess if you want to get on a drug trial you are chosen as opposed to applying in most cases, but its all ways worth asking your medical provider about them.
You can read more detail at this informative site
www.ClinicalTrials.gov

ClinicalTrials.gov United States National Institutes of Health offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions. A clinical trial (also clinical research) is a research study in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings.

When drug trials go Bad

Whenever I think of drug trials I think of guinea pigs and the tragic British drug trials of March 2006, A case of guinea pig beware I guess.
“It was the first time the drug TBN1412, designed to treat conditions such as rheumatoid arthritis and leukaemia, had been tested on humans.
Within hours of taking it on Monday, the six young volunteers had to be admitted to intensive care.
Ms Marshall, 35, whose boyfriend is critically ill, said the normally healthy 28-year-old’s face was so puffed, he “looks like the Elephant Man”.
She said he was completely lifeless, unable even to move an eyelid.
“They just keep saying he’s very, very sick and we are doing all we can,” she added. “

Such clinical trials were essential for the development of new and better treatments

The Medical Research Council said that while it was “an unfortunate and extremely rare event”, such clinical trials were essential for the development of new and better treatments.”

http://news.bbc.co.uk/2/hi/uk_news/england/london/4808836.stm

Best of Heath www.hcv.org.nz

August 8, 2009

Strategic Directions for Hepatitis C, New Zealand report HCTAG

Strategic Directions for Hepatitis C,

improving access to and uptake of hepatitis C treatment services.

HCTAG Hepatitis C Treatment Advisory Group
, NZ ministry of health

Thanks to NZ minister of health Hon Tony Ryall for releasing this draft copy

A few points that I found interesting the context for HCV Planning

The 50,000 figure with 1300 new infections per year, and we are treating around 600

“unless annual numbers of HCV positive New Zealanders receiving anti viral therapy  were to increase by % 300”

This would put the treatment numbers ahead of the new infections. At the moment we are going backwards every year with less treated than catching hepatitis C.

The current numbers are a joke, a token effort from The Ministry of health they are doing something just nowhere near enough to make an impact on the epidemic.

The pool of infected is growing every year, I could wear myself saying this, but fortunately this report lays it all out, in a much more logical manner then me.

Will anything change  ? NO .

The Ministry of health  are growing a massive public health disaster and there poor quality decision making and public health policy is growing the epidemic and future heath costs

Other recommendations

Key action areas increasing diagnosis

Key action area 3: Increasing the percentage of all people with HCV who have had the disease diagnosed

Key facts

An estimated 75 percent of the New Zealand population with HCV are unaware that they have the disease.

The major barriers to treatment in New Zealand with HCV infection are that people are unaware of their infection, or that the diagnosis is delayed until the liver disease is advanced, by, which time treatment is less effective. Because most people with HCV infection feel well or only have non-specific symptoms, early diagnosis requires targeted testing of all people who are at risk of previous exposure to HCV

• The largest undiagnosed pool of people with HCV are likely to be those aged 40-60 years old, who were infected 25-40 years ago, who at that time occasionally or even  once) injected illicit drugs, but went on to lead ‘conventional  Iives’.

This report should have been released months ago and the country can’t afford to wait to implement improvements. Absolute BS that it doesn’t in clued a implementation plan.

Its’ another reasonable report onHepatitis c in New Zealand it is a shame it will never be acted on and people will die and they will die increasingly in large numbers and they will die utterly preventable deaths. unless there is a significant increase in testing, diagnosis and treatment the number of people with end-stage liver disease – that is decompensated cirrhosis and liver cancer – will continue to increase . We are looking at: unnecessary death.

Draft copy released under OIA 29 July 09

http://www.hcv.org.nz/hepatitiscstrategynz.pdf (3 mgb file)

Meanwhile in England Hepatitis C out of control

undiagnosed; too few of those diagnosed are receiving the recommended treatment; and there are worrying regional variations in hepatitis C healthcare and delivery of treatment across the country. Of particular concern is the number of new infections each year – more than five times the number of people being successfully treated – indicating that prevention methods are not working. Clearly, the management of hepatitis C is out of control.

http://www.hepcoutofcontrol.org.uk/home.html

Hepatitis C is not slowing down in New Zealand it’s growing exponentially

RECENT TRENDS IN ILLEGAL DRUG USE IN NEW ZEALAND, 2006

a frightening reality vividly evident in this report

http://www.ndp.govt.nz/moh.nsf/pagescm/1109/$File/idms-2006-final-report-v2.pdf

“Forty-six percent of the frequent drug users had used injection equipment

after someone else in the past six months”

15.7 Summary of injecting behaviour

Forty-six percent of the frequent drug users had used injection equipment after someone else in

the past six months

Thirty-five percent of the frequent drug users had not always used a new sterile needle and

syringe when injecting drugs in the previous six months

The prevention effort of needle exchanges may have slowed the epidemic but even that seems questionable with behavior like above, the ongoing failure to address the problem is costing New Zealand dearly and is going to continue unless something is done.

Increase prevention efforts audit needle exchanges to optimise their services.

Anonymous community pharmacy blood testing for hep C  to try and reach the %75 of New Zealanders who are undiagnosed.

Show some leadership Ministry of Health and follow through invest in testing diagnosis and treatment.

best of health

www.hcv.org.nz

July 8, 2009

Hepatitis C New Service Improvements “delayed”

In the 2009 Health Budget

Savings can be generated in 2008/09 and 2009/10 by delaying contracting for services from within the draft Hepatitis C plan that have not yet been agreed and provided.

We don’t get ?

These are likely to include information and education services and DHB/Primary Care treatment services.

We get ?

  • A clinic in Christchurch for a three year proof of concept pilot programme to trial the provision of a Community Clinic
  • evaluation of the Christchurch clinic pilot
  • Haemophilia Foundation New Zealand - contracts to discharge obligations made under the Government’s Hepatitis C no-fault decision.

Hep C Service Improvements Cancelled

I think this is entirely unacceptable for the magnitude of the epidemic we are dealing with. Somebody does not get it.

We get a  Community Clinic in Christchurch that duplicates existing services in a community, that already has two treatment providers ?

We don’t  get information and education services and DHB/Primary Care treatment services for the rest of the country.

Which option benefits the most individuals and communities ?

What is going to make the most difference to the Hepatitis C epidemic in New Zealand ?

Christchurch Community Hepatitis C Clinic who is  it ?

Needle Exchange New Zealand, the Hepatitis C Resource Centre and Rodger Wright Needle Exchange Programme. A smoggy triangle of organisation’s based in Christchurch came up with the idea of a clinic for Christchurch.

The clinic will be governed through the Drug Injecting Services in Canterbury Trust which operates as the Rodger Wright Needle Exchange.

Christchurch PHOs, Partnership Health , Canterbury Community and Ministry of Health have provided financial assistance to support  the clinic .

If the Christchurch pilot proves successful, it is hoped similar clinics will be rolled out in other centres.

Christchurch already had a good level of hepatitis C treatment already according to the Christchurch DHB read more here


Where is the famous hepatitis C Plan ?

We have seen the mess that exiting servcies are in and it now seems a solution has been postponed. Yet we can’t even see this mythical Hepatitis C  plan to see what has been cut .

INVEST IN HEPATITIS C TREATMENT

It saves money you ,  It costs more to not treat, not addressing the problem is ensuring the future costs grow with the epidemic.

Health Economist, Ian Sheerin, from the National Addiction Centre at the Christchurch School of Medicine and Health Sciences says the lack of strategic screening, management and treatment for IDUs with Hepatitis C will cost the country dearly in coming years. He says there will be a multiplier effect in terms of increased health costs through extra GP visits, diagnostic tests, hospital outpatient follow-up, and inpatient admissions for liver cirrhosis and liver transplants.

“The figures should be of concern to health planners. There has been little official recognition of the implications of these escalating costs which will run into many millions of dollars in future,” says Ian Sheerin. ” My research predicts that there will be a cost of between $166 and $400 million over the next 30 years because of a lack of adequate treatment of Hepatitis C at present.”

Ian Sheerin says there is also the attitude amongst some members of the public that drug users don’t deserve any treatment at all. He says this is short-term thinking that will rebound on the taxpayer as more intravenous drug users end up in hospital with complications as a result of advanced Hepatitis C infection. With Hepatitis C, early intervention is arguably the most rational economic course to follow, resulting in fewer cases of severe liver disease while benefiting the patient at the same time.

Ian Sheerin National Addiction Centre Christchurch School of Medicine and Health Sciences University of Otago

Instead of making savings. These delays / savings in the 2009 budget  are generating greater future costs.

best of health

www.hcv.org.nz

July 2, 2009

Treatment waiting and liver fibrosis Hepatitis C New Zealand

July 2009

Treatment flow chart

I’ve been studying this Treatment flow chart from a New Zealand District Health board.

hepatitis C treatment-flowchart
I’m impressed by the level of detail and it does explain treatment and testing quite well.
Note Under perform liver biopsy we have the standard
Metavir classification for staging of hepatitis C liver disease (Biopsy)  But also some treatment decision information

Fibrosis Scale and Grading

Stage 0 No Fibrosis - No scarring NO TREATMENT RECOMMENDED REPORT BIOPSY IN 4 TO 5 YEARS

Stage 1 Portal fibrosis - Minimal scarring NO TREATMENT RECOMMENDED REPORT BIOPSY IN 4 TO 5 YEARS

Stage 2 Extra portal fibrosis - Scarring has occurred and extends outside the areas in the liver
that contains blood vessels CONSIDER TREATMENT

Stage 3 Bridging fibrosis is spreading and connecting to other areas that contain fibrosis TREAT

Stage 4 Cirrhosis or advanced scarring of the liver

I find it quite incredible that people won’t be treated until they reach advanced liver
Disease.From experience I know you can feel crap and have a really poor quality of life
with hepatitis C, before any fibrosis forms in your liver and the early stages are when
Hepatitis C is most likely to respond to treatment.

Suggesting a person waits until damage is more advanced seems questionable….

Apparently not having a liver biopsy would be is a better option as you “Consider treatment”

Its’ like playing Russian roulette with someone else’s health telling them to wait and see.

I haven’t got  a problem if it’s all explained to the patient and they make a informed decision, But patients are   usually at a disadvantage they lack information to make that decision and trust the health professional they know best….

Wonder how many people are waiting for their liver disease to progress till it becomes  “treatable”

My favourite quote of the month has to be
General (r) Tasawwar Hussain while speaking to audience, however, presented a new concept
saying that the occurrence of hepatitis B & C has increased with the increase in number
of health care facilities across Pakistan. “It convinced me to believe that unnecessary or
unsafe pricking at the health care facilities is one of the major causes of spread of
hepatitis in Pakistan and it should be discouraged religiously by medical professionals.”

So beware at all times of “ unnecessary or unsafe pricking at the healthcare facilities “

Meanwhile in Ireland :Irish Hep C health service faces a struggle

“the creation of a national register for people with hepatitis C, as a result of the lack
of concrete data on the prevalence of the virus amongst the Irish population.

The strategy also states all laboratory requests for hepatitis C serology must
contain full patient identifiers and full clinician details, as many notifications
continue to be incomplete even though it was made a notifiable disease in 2004.

Other recommendations include screening for hepatitis C and other blood-borne
diseases to those who attend services such as needle exchange programmes,
the establishment of an expert group to provide governance on clinical issues,
the development of interventions to delay and prevent transition from smoking
to injecting, the provision of supports to attend treatment, and the development
of peer support networks.

The most important requirement for drug clinics treating hepatitis C patients
is to have a clinical nurse specialist to coordinate and help administer care,
according to Dr Troy. “

New Zealand Hep C plan

Sounds good still waiting for the New Zealand Hep C plan I asked Hon Tony Ryall
our minister of health for a copy last week, wonder how long will have to wait to
see a copy of that……

Not as long as you going to have to wait for treatment if you live in ? which New Zealand Distinct Health Board

Best of Health

www.hcv.org.nz

June 23, 2009

Treatment responses Hepatitis C

Hepatitis C Treatment New Zealand District Health Boards

Ive been busy chasing District Health Boards to reply to our Hepatitis C treatment questions, Only three of the twenty one district health boards are yet to produce a reply and only one has ignored the request.

Treatment Outcomes and Terminology

There has been a bit of a discussion on the forums lately about monitoring treatment and the terminology
Rapid Viral Response: viral clearance at week four of treatment.
Early Viral Response (complete): viral clearance at week 12 of treatment.
Early Viral Response (partial): Significant drop in viral load at week 12 of treatment, ie. two log drop in viral load, eg. from 60,000 down to 600.
Non-Response: no significant drop in viral load after twelve weeks of treatment. This means you probably won’t be cured.
End-of-Treatment Response: whether or not the virus is detectable in your blood at the end of treatment (either six months or twelve months). This is good but it
doesn’t mean you are cured.
Sustained Viral Response: viral clearance as proved by a negative PCR result six months or more after treatment finishes. This is the result that people hope
for and is what doctors refer to when someone is successfully cured

http://www.hepc.org.au/documents/2009WYNTKweb-2MB.pdf

this info is from the new hep c council of NSW website  http://www.hepc.org.au/index.php?article=content/home

well worth a look.

Some Hepatitis C related video’s this blog


First up Teenager Jazzy was born with hepatitis C. This is her video diary about living with the condition
Produced and directed by Jazzy De Lisser “I will try treatment again”

A series of  informative videos from Nicole Cutler describes the various methods by which Hepatitis C is transmitted. www.hepatitis-central.com

Transmission

I  have been watching MusicKey ’s hepatitis C treatment Journey for a while now , GO MUSIC KEY  beat the virus

Another hepatitis C treatment video blog here

lots of encouragement to anyone on treatment and those contemplating it

best of health

www.hcv.org.nz

Older Posts »

Powered by WordPress